BACKGROUND: Myasthenia gravis is an autoimmune disease with a great impact on quality of life. Besides conservative treatment with mestinon and immunosuppressive medication, thymectomy is an established intervention that offers substantial improvements of the disease. Since the past decade, minimally invasive procedures have been performed. This study aimed to report on the long-term results for all the patients who underwent thymectomy for myasthenia gravis, paying special attention to postoperative disease-related outcome, quality of life, and differences regarding the operative approach. METHODS: This report describes a series of 131 patients with generalized myasthenia gravis who underwent thymectomy between 1980 and 2005. The clinical course data during the hospitalization and consultation in our outpatient clinic were reviewed, and survival data were generated. The patients were seen in the outpatient clinic, where a modified Osserman and quality-of-life score was evaluated at the end of the follow-up period for all surviving patients. RESULTS: A total of 106 patients with myasthenia gravis were followed up after thymectomy for a median time of 8 years (range, 1-27 years). Eight patients died during this period. The perioperative mortality rate was 0%, and the morbidity rate was 19.8%. The patients with thymoma and a high preoperative Osserman score had a significantly shorter survival. With minimally invasive procedures, the hospital stay was significantly shorter, and the rate for improvement of myasthenia gravis-associated symptoms was significantly higher. The rate of perioperative complications and myasthenia-related complications during the follow-up period showed no significant differences. CONCLUSIONS: Transsternal and minimally invasive thymectomy contribute to an improvement in myasthenia gravis symptoms for all subgroups. Surgery can be performed with low individual risks. In our trial, minimally invasive surgery was found to be superior in terms of improvement in myasthenia gravis-associated symptoms. Additionally, the hospital stay was shorter, and the patients felt less disturbed by direct effects of the operation. Therefore, minimally invasive thymectomy can be regarded as the treatment of choice for patients undergoing surgery for myasthenia gravis.
BACKGROUND:Myasthenia gravis is an autoimmune disease with a great impact on quality of life. Besides conservative treatment with mestinon and immunosuppressive medication, thymectomy is an established intervention that offers substantial improvements of the disease. Since the past decade, minimally invasive procedures have been performed. This study aimed to report on the long-term results for all the patients who underwent thymectomy for myasthenia gravis, paying special attention to postoperative disease-related outcome, quality of life, and differences regarding the operative approach. METHODS: This report describes a series of 131 patients with generalized myasthenia gravis who underwent thymectomy between 1980 and 2005. The clinical course data during the hospitalization and consultation in our outpatient clinic were reviewed, and survival data were generated. The patients were seen in the outpatient clinic, where a modified Osserman and quality-of-life score was evaluated at the end of the follow-up period for all surviving patients. RESULTS: A total of 106 patients with myasthenia gravis were followed up after thymectomy for a median time of 8 years (range, 1-27 years). Eight patients died during this period. The perioperative mortality rate was 0%, and the morbidity rate was 19.8%. The patients with thymoma and a high preoperative Osserman score had a significantly shorter survival. With minimally invasive procedures, the hospital stay was significantly shorter, and the rate for improvement of myasthenia gravis-associated symptoms was significantly higher. The rate of perioperative complications and myasthenia-related complications during the follow-up period showed no significant differences. CONCLUSIONS: Transsternal and minimally invasive thymectomy contribute to an improvement in myasthenia gravis symptoms for all subgroups. Surgery can be performed with low individual risks. In our trial, minimally invasive surgery was found to be superior in terms of improvement in myasthenia gravis-associated symptoms. Additionally, the hospital stay was shorter, and the patients felt less disturbed by direct effects of the operation. Therefore, minimally invasive thymectomy can be regarded as the treatment of choice for patients undergoing surgery for myasthenia gravis.
Authors: A Jaretzki; A S Penn; D S Younger; M Wolff; M R Olarte; R E Lovelace; L P Rowland Journal: J Thorac Cardiovasc Surg Date: 1988-05 Impact factor: 5.209
Authors: A E Papatestas; G Genkins; P Kornfeld; J B Eisenkraft; R P Fagerstrom; J Pozner; A H Aufses Journal: Ann Surg Date: 1987-07 Impact factor: 12.969
Authors: Nicholas R Hess; Inderpal S Sarkaria; Arjun Pennathur; Ryan M Levy; Neil A Christie; James D Luketich Journal: Ann Cardiothorac Surg Date: 2016-01
Authors: Phillip G Rowse; Anja C Roden; Frank M Corl; Mark S Allen; Stephen D Cassivi; Francis C Nichols; K Robert Shen; Dennis A Wigle; Shanda H Blackmon Journal: Ann Cardiothorac Surg Date: 2015-11
Authors: Bryan M Burt; Xiaopan Yao; Joseph Shrager; Alberto Antonicelli; Sukhmani Padda; Jonathan Reiss; Heather Wakelee; Stacey Su; James Huang; Walter Scott Journal: J Thorac Oncol Date: 2016-08-24 Impact factor: 15.609